{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-051759","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.138213+00:00","generated_at":"2026-06-05T06:29:48.628955+00:00","sec_items":["5.02","5.07","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aileron shareholders approve 3M share increase for equity plan, authorize 100M common shares","bullets":["Stockholders approved conversion of Series X Convertible Preferred into common; pro forma shares outstanding ~29.5M.","Authorized common shares increased from 45M to 100M via certificate of amendment effective Feb 28, 2024.","2021 Stock Incentive Plan amended to add 3,000,000 shares; compensation vote advisory '1 Year' frequency adopted.","Three Class III directors elected (Alves-Aivado, Ambros, von Rickenbach) to three-year terms.","Anticipated automatic conversion of ~12,087 Series X shares into 12,087,075 common shares on March 5, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-051759","json":"https://secwatch.observer/filing/0001193125-24-051759.json","markdown":"https://secwatch.observer/filing/0001193125-24-051759.md","text":"https://secwatch.observer/filing/0001193125-24-051759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524051759/0001193125-24-051759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524051759/d802393d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:29:48.628955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bec8042ffd8da21d73d44b6df625bab4aafdf3ff","claim":"Rein Therapeutics, Inc.: Increased authorized shares of common stock from 45,000,000 to 100,000,000 (effective 2024-02-28).","evidence_excerpt":"The Company filed the Certificate of Amendment to implement the increase in the number of authorized shares, which was effective upon filing, with the Secretary of State of the State of Delaware on February 28, 2024.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524051759/0001193125-24-051759-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}